Argeris N. Karabelas
Known title: DirectorCIK: 0001191229
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance. Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.
Transaction History
| RGNX | ▲ Buy | Grant | 9,807 | $0 | 5/29/2026 | View on chart |
| RGNX | ▲ Buy | Grant | 7,768 | $0 | 5/30/2025 | View on chart |
| RGNX | ▲ Buy | Option Exercise | 10,000 | $38K | 10/1/2024 | View on chart |
| RGNX | ▼ Sell | Open Market | 10,000 | $101K | 10/1/2024 | View on chart |
| RGNX | ▲ Buy | Option Exercise | 10,000 | $38K | 9/3/2024 | View on chart |
| RGNX | ▼ Sell | Open Market | 9,300 | $107K | 9/3/2024 | View on chart |
| RGNX | ▼ Sell | Open Market | 700 | $9K | 9/3/2024 | View on chart |
| RGNX | ▲ Buy | Option Exercise | 100 | $1K | 8/1/2024 | View on chart |
| RGNX | ▼ Sell | Open Market | 100 | $2K | 8/1/2024 | View on chart |
| RGNX | ▲ Buy | Option Exercise | 10,000 | $38K | 8/1/2024 | View on chart |
| RGNX | ▼ Sell | Open Market | 9,600 | $129K | 8/1/2024 | View on chart |
| RGNX | ▼ Sell | Open Market | 400 | $6K | 8/1/2024 | View on chart |
| RGNX | ▲ Buy | Option Exercise | 11,000 | $140K | 7/29/2024 | View on chart |
| RGNX | ▼ Sell | Open Market | 11,000 | $165K | 7/29/2024 | View on chart |
| RGNX | ▲ Buy | Option Exercise | 10,000 | $38K | 7/1/2024 | View on chart |
| RGNX | ▼ Sell | Open Market | 10,000 | $113K | 7/1/2024 | View on chart |
| RGNX | ▲ Buy | Grant | 4,790 | $0 | 5/31/2024 | View on chart |
| RGNX | ▲ Buy | Grant | 3,486 | $0 | 6/2/2023 | View on chart |
| BHC | ▲ Buy | Grant | 34,387 | $0 | 6/24/2022 | View on chart |
| RGNX | ▲ Buy | Grant | 3,010 | $0 | 6/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
RGNX Reports Positive 3-Year Data and Settles Patent Litigation
RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.
RGNX Reports Positive 3-Year Data and Settles Patent Litigation. RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.